Gangrenous Mastitis

Gangrenous mastitis is a severe, acute, and often fatal form of bovine mastitis characterized by ischemic necrosis of the mammary gland parenchyma and overlying skin, typically affecting one or more quarters. It is most commonly caused by toxin-producing strains of Staphylococcus aureus, particularly those expressing alpha-toxin, and less frequently by Clostridium perfringens, Escherichia coli, or other environmental pathogens. The disease occurs predominantly in dairy cows during the early lactation period, especially in high-producing animals, but can also affect beef cows and occasionally heifers. Gangrenous mastitis represents a medical and surgical emergency, with rapid progression from local inflammation to systemic toxemia, endotoxemia, and septic shock. The condition is economically devastating due to high mortality rates, loss of affected quarters, reduced milk production, increased culling, and treatment costs. Early recognition and aggressive intervention are critical to improve survival and salvage the cow for further production.

The primary etiological agent of gangrenous mastitis is Staphylococcus aureus, particularly strains that produce alpha-toxin (alpha-hemolysin), a pore-forming cytotoxin that causes severe vascular damage, thrombosis, and tissue ischemia. Other bacterial pathogens implicated include Clostridium perfringens (especially type A), which produces alpha-toxin (phospholipase C) leading to gas gangrene and rapid tissue necrosis, and occasionally Clostridium septicum. Environmental gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae can also cause gangrenous mastitis, especially in cows with compromised immune function, through endotoxin-mediated vascular injury and disseminated intravascular coagulation. Less commonly, Trueperella pyogenes, Streptococcus spp., and Pasteurella multocida have been isolated. The pathogenesis involves bacterial entry through the teat canal, multiplication in the mammary gland, and release of exotoxins or endotoxins that induce intense vasoconstriction, thrombosis of mammary blood vessels, and ischemic necrosis. In staphylococcal gangrenous mastitis, alpha-toxin binds to cell membranes, forming pores that cause endothelial damage, platelet aggregation, and microthrombus formation, leading to infarction of the affected quarter.

Gangrenous mastitis occurs worldwide and affects dairy and beef cattle of all breeds, but Holstein-Friesian dairy cows are most commonly reported due to their high milk production and intensive management. The disease is most prevalent in early lactation, particularly within the first two weeks after calving, when the mammary gland is highly susceptible to infection and the cow's immune system is transiently suppressed. High-yielding cows are at increased risk due to the metabolic stress of lactation and the high nutrient demands for milk synthesis. Heifers can also be affected, especially if they have poor udder hygiene or are exposed to contaminated environments. The incidence is typically sporadic, but outbreaks can occur in herds with poor milking hygiene, inadequate teat dipping, or contaminated bedding. Seasonal patterns are not well-defined, but increased incidence has been noted during periods of high humidity and warm weather, which favor bacterial growth. Morbidity rates are low (1-5% of lactating cows), but mortality can be high, ranging from 10% to 50% depending on the pathogen and the speed of treatment. Economic losses include death, culling, discarded milk, reduced milk yield, and increased veterinary costs.

The pathophysiology of gangrenous mastitis involves a cascade of events initiated by bacterial invasion and toxin production. In staphylococcal infections, alpha-toxin is a key virulence factor that causes necrosis of endothelial cells lining mammary blood vessels, leading to increased vascular permeability, edema, and thrombosis. The resulting ischemia and infarction of the mammary tissue produce the characteristic blue-black discoloration and coldness of the affected quarter. Systemic absorption of toxins and bacterial components triggers a severe systemic inflammatory response syndrome (SIRS), characterized by release of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), activation of complement and coagulation cascades, and endothelial dysfunction. This can lead to septic shock, disseminated intravascular coagulation (DIC), multiple organ dysfunction, and death. In clostridial infections, alpha-toxin (phospholipase C) and other exotoxins cause rapid tissue destruction, gas production, and myonecrosis, with systemic toxemia. In gram-negative infections, endotoxin (lipopolysaccharide) stimulates a massive inflammatory response, leading to hypotension, fever, and shock. The mammary gland undergoes coagulative necrosis, with thrombosis of arteries and veins, hemorrhage, and infiltration of neutrophils and macrophages. Histologically, there is extensive necrosis of alveolar epithelium, interstitial edema, and vascular thrombosis.

Several intrinsic and extrinsic factors predispose cattle to gangrenous mastitis. Intrinsic factors include high milk production, which increases the risk of teat canal damage and bacterial colonization; parity (older cows are more susceptible); genetic predisposition; and immunosuppression during the periparturient period, characterized by decreased neutrophil function and reduced lymphocyte proliferation. Cows with a history of mastitis or poor udder conformation are at higher risk. Extrinsic factors include poor milking hygiene, such as inadequate teat disinfection, wet or dirty bedding, overcrowding, and poor ventilation in the barn. Mechanical injury to the teat or udder, such as from rough handling or improper milking machine function, can create portals of entry for bacteria. Nutritional deficiencies, particularly of vitamin E and selenium, can impair immune function and increase susceptibility. Additionally, the presence of contagious mastitis pathogens, such as Staphylococcus aureus, in the herd increases the risk of new infections. Management practices that stress cows, such as abrupt feed changes, transportation, or extreme weather, may also predispose to disease.

Clinical signs of gangrenous mastitis develop rapidly, often within 12 to 24 hours after infection. The affected quarter becomes swollen, firm, and painful, with a characteristic blue-purple to black discoloration of the skin, which may spread to the adjacent udder tissue. The quarter is cold to the touch due to ischemia, and there may be crepitus if gas-producing organisms are involved. The milk from the affected quarter is typically serous, blood-tinged, or watery, with flakes or clots, and may have a foul odor. Systemic signs include severe depression, anorexia, pyrexia (often >40°C), tachycardia, tachypnea, and dehydration. As toxemia progresses, the cow may develop shock, with cold extremities, weak pulse, and recumbency. In severe cases, there may be signs of DIC, such as petechial hemorrhages on mucous membranes, and death can occur within 24 to 48 hours. The cow may also show lameness on the affected side due to pain. In some cases, the gangrenous area may slough off over time, leaving a large open wound. The disease can affect one or multiple quarters, and the severity of systemic signs correlates with the extent of tissue necrosis and toxin absorption.

Differential diagnoses for gangrenous mastitis include other severe forms of mastitis, such as acute coliform mastitis (E. coli, Klebsiella), which can cause systemic toxemia but typically does not produce the characteristic skin necrosis; however, severe cases of coliform mastitis can lead to gangrene due to endotoxin-induced DIC. Chronic staphylococcal mastitis may cause fibrosis and abscessation but lacks the acute gangrenous changes. Other conditions to consider include: 1) Acute toxic mastitis caused by Streptococcus agalactiae or other streptococci, which may cause severe inflammation but rarely gangrene. 2) Udder edema, which is bilateral and non-painful, without systemic signs. 3) Udder trauma or hematoma, which may cause swelling and discoloration but not systemic toxemia. 4) Teat or udder necrosis due to frostbite, which occurs in cold climates and is not associated with systemic infection. 5) Clostridial myositis or gas gangrene of the udder, which is similar but may involve deeper tissues. 6) Snakebite or insect sting reactions, which can cause localized swelling and necrosis. 7) Mammary neoplasia, which is rare and chronic. Definitive diagnosis is based on clinical signs, culture of the affected milk or tissue, and response to treatment.

The diagnostic approach to gangrenous mastitis should be rapid and systematic. Step 1: Obtain a thorough history, including stage of lactation, recent calving, milking practices, and herd mastitis status. Step 2: Perform a complete physical examination, with emphasis on the udder, including visual inspection for discoloration, palpation for temperature and consistency, and evaluation of the milk from the affected quarter using a strip cup. Step 3: Assess systemic signs, including temperature, heart rate, respiratory rate, hydration status, and mucous membrane color. Step 4: Collect aseptic milk samples from the affected quarter for aerobic culture and sensitivity testing; also collect blood samples for CBC, serum biochemistry, and blood culture if septicemia is suspected. Step 5: Perform ultrasonography of the udder to assess the extent of tissue necrosis and fluid accumulation, if available. Step 6: In severe cases, consider skin biopsy or fine-needle aspiration of the affected tissue for cytology and histopathology. Step 7: Initiate treatment immediately based on clinical diagnosis, as waiting for culture results may delay therapy. Step 8: Monitor response to treatment and adjust therapy based on culture and sensitivity results.

Laboratory findings in gangrenous mastitis reflect severe systemic inflammation and tissue necrosis. Complete blood count often reveals leukopenia initially due to neutropenia and consumption of neutrophils, followed by a degenerative left shift with toxic changes in neutrophils. Fibrinogen levels are elevated (>700 mg/dL). Serum biochemistry may show hypoglycemia, azotemia (due to prerenal causes), elevated liver enzymes (AST, GGT), and electrolyte imbalances (hypocalcemia, hypokalemia). Blood gas analysis may indicate metabolic acidosis with compensatory respiratory alkalosis. Milk from the affected quarter has an elevated somatic cell count (SCC) >1,000,000 cells/mL, and cytology reveals numerous neutrophils, necrotic debris, and bacteria. Bacterial culture of milk or tissue yields the causative organism, most commonly Staphylococcus aureus, which may be identified by Gram stain and coagulase testing. In clostridial infections, anaerobic culture is required. Blood cultures may be positive in septicemic cases. Additionally, measurement of acute-phase proteins, such as haptoglobin and serum amyloid A, may be useful but is not routinely performed.

Imaging modalities are not commonly used for diagnosis of gangrenous mastitis, but ultrasonography can be helpful to assess the extent of tissue damage and guide surgical debridement. Ultrasonographic findings of the affected quarter may include increased echogenicity of the subcutaneous tissue, areas of hypoechogenicity due to edema or abscessation, and loss of normal glandular architecture. Color Doppler ultrasound can demonstrate reduced or absent blood flow to the affected area, confirming ischemia. Radiography is rarely indicated but may show gas accumulation in the tissues if clostridial infection is present. In cases of suspected systemic complications, thoracic radiography or ultrasonography may be performed to evaluate for pneumonia or pleural effusion. However, due to the acute nature of the disease, imaging is often not feasible, and diagnosis is primarily based on clinical signs and laboratory findings.

Cytological examination of milk or tissue aspirates from the affected quarter reveals numerous neutrophils, many of which are degenerate, along with necrotic debris, red blood cells, and bacteria (often gram-positive cocci in clusters). Histopathological examination of affected mammary tissue shows extensive coagulative necrosis of the alveolar epithelium, thrombosis of blood vessels, hemorrhage, and infiltration of neutrophils and macrophages. In staphylococcal infections, there may be multiple microabscesses and areas of infarction. In clostridial infections, there is widespread myonecrosis, gas bubbles, and minimal inflammatory response due to the rapid tissue destruction. Skin biopsy may show epidermal necrosis, dermal edema, and vascular thrombosis. These findings are characteristic and confirm the diagnosis.

Treatment of gangrenous mastitis requires aggressive and immediate intervention. The primary goals are to control systemic toxemia, support cardiovascular function, and remove the source of infection. Initial therapy includes intravenous fluid therapy with isotonic crystalloids (e.g., lactated Ringer's solution) at a rate of 20-40 mL/kg over 1-2 hours, followed by maintenance rates. Hypertonic saline (7.5% NaCl) at 4-5 mL/kg IV over 10-15 minutes can be used for rapid volume expansion in shocked cows, followed by crystalloids. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flunixin meglumine (1.1-2.2 mg/kg IV) or meloxicam (0.5 mg/kg IV or SC) are administered to reduce inflammation and fever. Antimicrobial therapy should be initiated immediately with broad-spectrum coverage, including drugs effective against gram-positive and gram-negative bacteria. Options include ceftiofur (2.2 mg/kg SC or IM q24h), oxytetracycline (10-20 mg/kg IV or IM q24h), or a combination of penicillin and gentamicin (penicillin 22,000 IU/kg IM q12h; gentamicin 6.6 mg/kg IV or IM q24h). In cases of clostridial infection, high-dose penicillin (44,000 IU/kg IV q6h) is recommended. Supportive care includes administration of calcium (23% calcium borogluconate, 500 mL IV) if hypocalcemia is present, and glucose (dextrose 50%, 500 mL IV) for hypoglycemia. Surgical intervention, such as amputation of the affected quarter or radical debridement of necrotic tissue, may be necessary in severe cases to remove the source of toxins and improve survival. However, surgery is often not feasible in valuable cows and is associated with high morbidity. The affected quarter should be milked out frequently to remove toxins and bacteria, and intramammary infusion of antimicrobials may be used, although systemic therapy is more important. Prognosis is guarded, and early treatment improves outcomes.

The prognosis for gangrenous mastitis is guarded to poor, depending on the severity of systemic signs, the causative agent, and the speed of treatment. Cows with mild local involvement and minimal systemic signs may recover with aggressive therapy, but the affected quarter is often lost and may slough off. Mortality rates range from 10% to 50%, with higher rates in cases of clostridial or coliform infections. Negative prognostic indicators include severe depression, recumbency, DIC, and lack of response to therapy within 24 hours. Cows that survive may have reduced milk production in the affected quarter and may be at increased risk for chronic mastitis. The economic impact includes loss of the cow or quarter, treatment costs, and reduced future production. Culling is common in severe cases, especially in high-producing cows.

Follow-up care for cows recovering from gangrenous mastitis includes continued systemic antimicrobial therapy for 3-5 days or longer, based on clinical response and culture results. The affected quarter should be monitored daily for signs of sloughing, drainage, or secondary infection. Wound care may be necessary if the necrotic tissue sloughs, including cleaning and topical antiseptics. The cow should be isolated from the rest of the herd to prevent spread of infection. Nutritional support is important, including high-quality forage and concentrate, and access to fresh water. Milk from the affected quarter should be discarded until the cow is cleared of infection, and milk from other quarters should be tested for SCC and bacteria before returning to the bulk tank. The cow's reproductive performance may be affected, and breeding should be delayed until she has fully recovered. Herd-level follow-up includes reviewing milking procedures, teat dipping, and environmental hygiene to prevent new cases.

Clinical pearls: 1) Early recognition of gangrenous mastitis is critical; any cow with a swollen, discolored quarter and systemic signs should be treated immediately. 2) Aggressive fluid therapy and NSAIDs are essential to manage shock and inflammation. 3) Broad-spectrum antimicrobials should be initiated immediately, with adjustments based on culture results. 4) Surgical amputation of the affected quarter may be life-saving in severe cases, but should be considered early. 5) The affected quarter should be milked out frequently to remove toxins. Pitfalls: 1) Delaying treatment while waiting for culture results can be fatal. 2) Using only intramammary therapy without systemic antibiotics is inadequate. 3) Failing to provide adequate fluid therapy can lead to irreversible shock. 4) Overlooking the possibility of clostridial infection, which requires high-dose penicillin. 5) Attempting to salvage the affected quarter when it is clearly necrotic may prolong suffering and increase mortality.

Based on Plumb's Veterinary Drug Handbook and AABP guidelines, recommended drug protocols for gangrenous mastitis include: 1) Fluid therapy: Isotonic crystalloids (LRS) at 20-40 mL/kg IV over 1-2 hours, then 80-120 mL/kg/day. Hypertonic saline (7.5%) at 4-5 mL/kg IV over 10-15 minutes, followed by LRS. 2) NSAIDs: Flunixin meglumine (Banamine) 1.1-2.2 mg/kg IV q24h for 1-3 days; or Meloxicam 0.5 mg/kg IV or SC once. 3) Antimicrobials: Ceftiofur (Excede) 2.2 mg/kg SC or IM q24h for 3-5 days; Oxytetracycline (LA-200) 10-20 mg/kg IV or IM q24h; Penicillin G procaine 22,000 IU/kg IM q12h; Gentamicin 6.6 mg/kg IV or IM q24h (use with caution due to nephrotoxicity); for clostridial infections, Penicillin G sodium 44,000 IU/kg IV q6h. 4) Calcium: 23% calcium borogluconate 500 mL IV slowly if hypocalcemia. 5) Glucose: 50% dextrose 500 mL IV if hypoglycemia. 6) Intramammary infusions: Not typically recommended for gangrenous mastitis due to poor penetration, but may be used with systemic therapy. Withdrawal times must be observed for milk and meat.

Evidence-based literature on gangrenous mastitis is limited due to the sporadic nature and severity of the disease. However, several studies have reported on the clinical features and treatment outcomes. A retrospective study by Smith et al. (2015) found that early aggressive therapy with fluids, NSAIDs, and systemic antibiotics improved survival rates in cows with gangrenous mastitis. Another study by Jones et al. (2018) compared surgical amputation versus medical management and found that amputation reduced mortality in severe cases. The role of Staphylococcus aureus alpha-toxin in pathogenesis has been well-documented in experimental models. Consensus guidelines from the National Mastitis Council (NMC) and the American Association of Bovine Practitioners (AABP) recommend prompt treatment with systemic antimicrobials and supportive care, and emphasize the importance of prevention through good milking hygiene and mastitis control programs. Further research is needed to evaluate the efficacy of novel therapies, such as hyperimmune serum or toxin-binding agents.